for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Seattle Genetics, Inc.

SGEN.OQ

Latest Trade

101.36USD

Change

13.96(+15.97%)

Volume

716,409

Today's Range

96.51

 - 

101.40

52 Week Range

50.73

 - 

101.40

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Seattle Genetics And Astellas Announce U.S. FDA Grants Priority Review For Enfortumab Vedotin Biologics License Application In Locally Advanced Or Metastatic Urothelial Cancer

Sept 16 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS AND ASTELLAS ANNOUNCE U.S. FDA GRANTS PRIORITY REVIEW FOR ENFORTUMAB VEDOTIN BIOLOGICS LICENSE APPLICATION IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.SEATTLE GENETICS INC - FOOD & DRUG ADMINISTRATION SETS PRESCRIPTION DRUG USER FEE ACTION DATE FOR MARCH 15, 2020.

Seattle Genetics Announces Pricing Of Public Offering Of Common Stock

July 23 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 7.1 MILLION COMMON SHARES PRICED AT $70.00PER SHARE.SEATTLE GENETICS - GROSS PROCEEDS TO SEATTLE GENETICS FROM OFFERING ARE EXPECTED TO BE ABOUT $500 MILLION.

Seattle Genetics Announces Proposed Public Offering Of Common Stock

July 23 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 6.00 MILLION COMMON SHARES.SEATTLE GENETICS - SEES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING COMMERCIALIZATION OF ADCETRIS IN UNITED STATES AND CANADA, OTHERS.

Seattle Genetics Reports Q2 Loss Per Share Of $0.49

July 16 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE ESTIMATE $-0.39 -- REFINITIV IBES DATA.TOPLINE RESULTS FROM TUCATINIB HER2CLIMB PIVOTAL TRIAL EXPECTED IN 2019.QTRLY TOTAL REVENUES INCREASED TO $218.4 MILLION VERSUS $170.2 MILLION.AS OF JUNE 30, 2019, CASH AND INVESTMENTS WERE $376.1 MILLION.Q2 REVENUE VIEW $189.8 MILLION -- REFINITIV IBES DATA.NOW SEES 2019 COLLABORATION AND LICENSE AGREEMENT REVENUES $110 MILLION TO $125 MILLION.

Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA

July 16 (Reuters) - Seattle Genetics Inc <SGEN.O>::ASTELLAS AND SEATTLE GENETICS ANNOUNCE SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO FDA FOR ENFORTUMAB VEDOTIN FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.

Seattle Genetics And Astellas Announce Submission Of Biologics License Application To FDA

July 16 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS AND ASTELLAS ANNOUNCE SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO FDA FOR ENFORTUMAB VEDOTIN FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.

Seattle Genetics Announces Analyses Of Echelon-1 And Echelon-2 Phase 3 Clinical Trials Of Adcetris

June 3 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS ANNOUNCES ADDITIONAL ANALYSES OF ECHELON-1 AND ECHELON-2 PHASE 3 CLINICAL TRIALS OF ADCETRIS® (BRENTUXIMAB VEDOTIN) AT THE 2019 ASCO ANNUAL MEETING.SEATTLE GENETICS - 3-YEAR UPDATE OF ECHELON-1 TRIAL CONTINUES TO SHOW SUPERIOR CLINICAL ACTIVITY OF ADCETRIS WITH CHEMOTHERAPY VERSUS ABVD IN FRONTLINE HODGKIN LYMPHOMA.

Seattle Genetics Says Canada Approves Adcetris In Combination With AVD Chemotherapy

May 3 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS ANNOUNCES PROGRESS IN EXPANDING ADCETRIS (BRENTUXIMAB VEDOTIN) INDICATIONS IN CANADA.SEATTLE GENETICS INC - HEALTH CANADA APPROVES ADCETRIS IN COMBINATION WITH AVD CHEMOTHERAPY FOR TREATMENT OF PREVIOUSLY UNTREATED HODGKIN LYMPHOMA.SEATTLE GENETICS - SNDA SUBMITTED TO CANADA FOR ADCETRIS IN COMBINATION WITH CHP IN PATIENTS WITH UNTREATED CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMA.SEATTLE GENETICS INC - GRANTED A PRIORITY REVIEW DESIGNATION FOR SUPPLEMENTAL NEW DRUG SUBMISSION FOR EXPANDED USE OF ADCETRIS.

Seattle Genetics Q1 Loss Per Share $0.08

April 25 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.08.Q1 EARNINGS PER SHARE ESTIMATE $-0.29 -- REFINITIV IBES DATA.Q1 REVENUE $195.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $186.8 MILLION.SEATTLE GENETICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.TOTAL REVENUES IN Q1 ENDED MARCH 31, 2019 INCREASED TO $195.2 MILLION, COMPARED TO $140.6 MILLION FOR SAME PERIOD IN 2018.ADCETRIS NET SALES FOR U.S. AND CANADA IN Q1 WERE $135.0 MILLION $95.4 MILLION IN Q1 OF 2018.QTRLY LOSS PER SHARE $0.08.SEES 2019 ADCETRIS NET PRODUCT SALES $610 MILLION TO $640 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.30 -- REFINITIV IBES DATA.Q1 REVENUE VIEW $187.1 MILLION -- REFINITIV IBES DATA.

Seattle Genetics Sees FY 2019 Revenue $790 Mln To $840 Mln

Feb 7 (Reuters) - Seattle Genetics Inc <SGEN.O>::SEATTLE GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.SEES FY 2019 REVENUE $790 MILLION TO $840 MILLION.Q4 LOSS PER SHARE $0.75.Q4 EARNINGS PER SHARE ESTIMATE $-0.42 -- REFINITIV IBES DATA.TOTAL REVENUES IN Q4 INCREASED TO $174.5 MILLION COMPARED TO $129.6 MILLION.ADCETRIS NET SALES IN U.S. AND CANADA FOR Q4 WERE $132.1 MILLION, A 58 PERCENT INCREASE.SEES 2019 ADCETRIS NET PRODUCT SALES $610 MILLION TO $640 MILLION.SEES 2019 COLLABORATION AND LICENSE AGREEMENT REVENUES $95 MILLION TO $110 MILLION.SEES 2019 ROYALTY REVENUES $85 MILLION TO $90 MILLION.SEES 2019 RESEARCH AND DEVELOPMENT EXPENSES $600 MILLION TO $650 MILLION.SEES 2019 NON-CASH COSTS (PRIMARILY ATTRIBUTABLE TO SHARE BASED COMPENSATION) $135 MILLION TO $145 MILLION.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up